Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Toxin-based therapeutic approaches.

Shapira A, Benhar I.

Toxins (Basel). 2010 Nov;2(11):2519-83. doi: 10.3390/toxins2112519. Epub 2010 Oct 28. Review.

2.

Anthrax fusion protein therapy of cancer.

Frankel AE, Powell BL, Duesbery NS, Vande Woude GF, Leppla SH.

Curr Protein Pept Sci. 2002 Aug;3(4):399-407. Review.

PMID:
12370003
3.

Targeted toxins in brain tumor therapy.

Li YM, Hall WA.

Toxins (Basel). 2010 Nov;2(11):2645-62. doi: 10.3390/toxins2112645. Epub 2010 Nov 1. Review.

4.

Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

Weidle UH, Tiefenthaler G, Schiller C, Weiss EH, Georges G, Brinkmann U.

Cancer Genomics Proteomics. 2014 Jan-Feb;11(1):25-38. Review.

PMID:
24633317
5.

Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.

Mathew M, Verma RS.

Cancer Sci. 2009 Aug;100(8):1359-65. doi: 10.1111/j.1349-7006.2009.01192.x. Epub 2009 May 19. Review.

6.

Recombinant toxins as novel therapeutic agents.

Pastan I, Chaudhary V, FitzGerald DJ.

Annu Rev Biochem. 1992;61:331-54. Review. No abstract available.

PMID:
1497314
7.

Chimeric fusion proteins--Pseudomonas exotoxin-based.

Kreitman RJ.

Curr Opin Investig Drugs. 2001 Sep;2(9):1282-93. Review.

PMID:
11717817
8.

Immunotoxins and recombinant toxins in the treatment of solid carcinomas.

Theuer CP, Pastan I.

Am J Surg. 1993 Sep;166(3):284-8. Review.

PMID:
8368439
9.

Immunotoxins in the treatment of hematologic malignancies.

Kreitman RJ, Pastan I.

Curr Drug Targets. 2006 Oct;7(10):1301-11. Review.

PMID:
17073592
10.

Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.

Kawakami K, Nakajima O, Morishita R, Nagai R.

ScientificWorldJournal. 2006 Jul 7;6:781-90. Review.

11.

Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.

Kreitman RJ.

BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001. Review.

12.

Patents on immunotoxins and chimeric toxins for the treatment of cancer.

Bachran C, Sutherland M, Bachran D, Fuchs H.

Recent Pat Drug Deliv Formul. 2007;1(2):105-15. Review.

PMID:
19075878
13.

Immunotoxins: the role of the toxin.

Antignani A, Fitzgerald D.

Toxins (Basel). 2013 Aug 21;5(8):1486-502. doi: 10.3390/toxins5081486. Review.

14.

Entry of protein toxins in polarized epithelial cells.

Melby EL, Jacobsen J, Olsnes S, Sandvig K.

Cancer Res. 1993 Apr 15;53(8):1755-60.

15.

Advances in anticancer immunotoxin therapy.

Alewine C, Hassan R, Pastan I.

Oncologist. 2015 Feb;20(2):176-85. doi: 10.1634/theoncologist.2014-0358. Epub 2015 Jan 5. Review.

16.

Diphtheria toxin-based targeted toxin therapy for brain tumors.

Li YM, Vallera DA, Hall WA.

J Neurooncol. 2013 Sep;114(2):155-64. doi: 10.1007/s11060-013-1157-8. Epub 2013 May 22. Review.

PMID:
23695514
17.

Immunotoxins: is there a clinical value?

Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A.

Ann Oncol. 1994;5 Suppl 1:97-103. Review.

PMID:
7826425
18.

Immunotoxins.

Press OW.

Biotherapy. 1991;3(1):65-76. Review.

PMID:
2009215
19.

Antibody-toxin conjugates: a new approach to cancer therapy.

McIntosh DP.

Adv Biotechnol Processes. 1984;3:111-39. Review. No abstract available.

PMID:
6399840
20.

Bacterial Toxins for Oncoleaking Suicidal Cancer Gene Therapy.

Pahle J, Walther W.

Recent Results Cancer Res. 2016;209:95-110. doi: 10.1007/978-3-319-42934-2_7. Review.

PMID:
28101690

Supplemental Content

Support Center